早产是导致围产期发病率和死亡率的主要原因之一。早产对新生儿的存活以及之后的健康都是一个非常严重的问题,早产儿的护理费用也较高。虽然产科学、围产期学和新生儿学已有较大的进展,但是早产儿存活率只增加了约1.4%。K-V制药公司研发的己酸羟孕酮(hydroxyprogesterone caproate)注射剂(商品名为Makena)于2011年2月4日获得美国食品药品管理局(FDA)批准上市,用于至少有一次自发性早产史的孕妇以降低早产风险。该药物活性成分是羟孕酮己酸酯,化学名为17α-羟基孕酮己酸酯(17α-OHPC),分子 Premature delivery is one of the major causes of perinatal morbidity and mortality. Preterm birth is a very serious problem for the survival of the newborn and for later health. The cost of nursing premature babies is also high. Although there has been considerable progress in obstetrics, perinatal and neonatal science, the survival rate of preterm children has increased by only about 1.4%. Kyproxene hydroxyprogesterone caproate injection (Makena) developed by KV Pharmaceuticals was approved by the U.S. Food and Drug Administration (FDA) on February 4, 2011 for at least one spontaneous preterm birth Pregnant women to reduce the risk of preterm birth. The active pharmaceutical ingredient is hydroxyprogesterone caproate, a chemical name 17α-hydroxyprogesterone caproate (17α-OHPC), a molecule